SBH Sciences

The future of cancer research is rapidly evolving, driven by cutting-edge technologies that offer deeper insights into cellular metabolism and therapeutic responses. Seahorse technology, an advanced metabolic analysis tool, transforms how researchers identify metabolic vulnerabilities specific to cancer cells. In this exclusive Q&A, Raphael Nir speaks with guests Miguel Luiz Batista Junior, CEO/CSO and Director of Adipose Tissue modeling at Bonds Biosystems, and Rafael Dariolli, CEO/CSO and Director of Cardiovascular modeling at Bonds Biosystems, both of whom have successfully co-Founded Bonds Biosystems. Click the link to learn how Seahorse Technology has the power to transform drug development as we know it. https://lnkd.in/eUW5x-7d #Seahorsetechnology #cancerresearch #aligenttechnologies #cellularmetabolism #tumoroids

Last week, we explored the power of AlphaLISA — a high-sensitivity, no-wash assay technology. This week, we're diving into HTRF (Homogeneous Time-Resolved Fluorescence), a versatile and robust technology used across the biotech industry in applications like drug discovery, biomarker identification, and life sciences research. HTRF combines fluorescence resonance energy transfer (FRET) with time-resolved measurements to deliver high sensitivity and specificity in molecular interaction detection, making it highly suitable for high-throughput screening. Key Benefits of HTRF: ✅ No-wash, homogenous assay format ✅High sensitivity and specificity ✅Versatile across protein-protein, receptor-ligand, and more interactions ✅Ideal for complex assays and large-scale screening Please check out our latest blog to learn how HTRF can boost your research workflow. https://lnkd.in/e2jn8zjV #HTRF #Highthroughputscreening #AssayTechnology #ContractResearchOrganization #CustomAssayDevelopment

Enhance Your Research with AlphaLISA! AlphaLISA is a powerful high-throughput, no-wash assay technology that delivers exceptional sensitivity and scalability for biomolecule detection. Widely used across the biotech industry — from drug discovery and biomarker research to broader life science applications — AlphaLISA stands out for its robustness, flexibility, and versatility. SBH Sciences can perform any of the dozens of developed AlphaLISA assays to support your research and development needs. Please check out our latest blog to learn more! https://lnkd.in/eYBFv8MV #AlphaLISA #Immunoassays #Highspecifcity #Highsensitivity #ContractResearchOrganization    

Exciting news from SBH Sciences 🎉 We are proud to announce that SBH Sciences is officially a Certified Service Provider (CSP) on the Ella instrument by Bio-Techne! Congratulations to Adam Nir and Dylan Briggs for earning their certifications! 👏 Ella is a powerhouse for automated, multiplex ELISA-based immunoassays, delivering rapid and precise biomarker analysis. As a Contract Research Organization dedicated to advancing research and improving patient lives, we look forward to collaborating with you to streamline your immunoassay needs. Please connect with us to learn how Ella can support your research. We would be delighted to assist you! https://lnkd.in/ek65UGMh Thank you, Bio-Techne! https://lnkd.in/euqys6jn #CertifiedServiceProvider #Ella #BioTechne #ContractResearchOrganization #AutomatedELISA

Last week, we highlighted the capabilities of the Ella automated ELISA system, which offers speed and automation in quantitative analysis. While Ella is an excellent tool, it's important to recognize the continued value of ELISA (enzyme-linked immunosorbent assay) methods for its precision, flexibility, and cost-effectiveness. Please check out this week's blog to learn how SBH was tasked with developing a custom ELISA for a novel biomarker not commercially available on platforms like Ella, Luminex, or standard ELISA kits, and the process we followed to successfully provide tailored solutions to meet our client's specific needs. https://lnkd.in/e2bjVGYf #ELISA #AutomatedElla #ELISAkits #Biomarkers #ContractResarchOrganization

Ready to elevate your research? At SBH Sciences, we offer the Ella automated ELISA system, a next-generation benchtop platform designed to deliver accurate, reproducible data with no manual steps required. By automating the process with single-use cartridges and microfluidic technology, Ella minimizes contamination risk, reduces sample and reagent consumption, and delivers precise results in under 90 minutes. Check out our data showcasing Ella's exceptional precision, stability, and accuracy. Curious about how Ella can benefit your research? Learn more about the advantages of Ella here. https://lnkd.in/e8zipFrV Contact us today to discuss how our cutting-edge technology can add value to your research! The Ella instrument by Bio-Techne automates every step of the immunoassay workflow, helping to minimize user error while ensuring highly precise and reproducible results. Click here to learn more. https://lnkd.in/enxnQDgi #ELLA #BioTechne #AutomedELISA #Multiplexing #contractresearchorganization

Today, we're spotlighting Adam Nir, Chief Diagnostic Officer, whose expertise, leadership, and problem-solving skills have been instrumental in driving innovation and advancing biomarker research at SBH Sciences and SBH Diagnostics. With over 11 years at SBH Sciences and SBH Diagnostics, Adam leads the biomarker department with precision, mentoring a team of five scientists while ensuring the seamless execution of complex, high-impact projects. His deep scientific knowledge of ELISA development, multiplex analysis, and automated Western technology enable SBH to deliver cutting-edge, reliable results that fuel breakthrough discoveries. In 2024, Adam's group assisted over 40 biotech companies, providing expert biomarker analysis and diagnostic support. Our lab adheres to Good Laboratory Practice (GLP) guidelines to ensure the integrity and reproducibility of our data. Beyond the lab, Adam plays a crucial strategic role, supporting clients with comprehensive data analysis, streamlined project workflows, and expertise that drives research and innovation forward. His dedication, problem-solving acumen, and unwavering commitment to scientific excellence have strengthened our team, elevated our capabilities, and reinforced SBH Sciences and SBH Diagnostics as a trusted CRO. Thank you, Adam, for your outstanding contributions!

Today is #RareDiseaseDay where we recognize the resilience of over 300 million people worldwide living with a rare disease. Each disease presents unique challenges, often requiring highly specialized treatments and understanding. In conditions like POEMS syndrome, characterized by elevated IL-12, IL-6, a nuanced approach focusing on cytokine modulation rather than solely suppression may offer more targeted therapeutic benefits. SBH Early Discovery CRO brings over 16 years of specialized experience in high-purity human IL-12 production and cell-based assays. Our focus is on developing a deeper understanding of cytokine modulation, aiming to contribute to more effective and targeted treatments. Check out this recent article on POEMS syndrome. #rarediseaseresearch #rarediseaseday #POEMSsyndrome #IL12 #IL6 https://lnkd.in/evkgdM3C

SBH Sciences is thrilled to welcome Dr. Tami Rashal Rashal as our new Chief Medical Officer (CMO) for SBH Sciences and SBH Bioventure. Dr. Rashal is a distinguished, board-certified hematologist-oncologist and entrepreneur with over a decade of experience in clinical research, drug development, and hospital practice. She has successfully led the submission of three NDAs and multiple INDs, proving her expertise in advancing novel therapies to her patients. Before joining SBH Sciences. Dr. Rashal was the CEO of Merlin Health, an AI-based clinical trial decision-making tool, where she demonstrated her ability to drive complex projects and lead high-performing cross-functional teams to success. Dr. Rashal’s vision for SBH Sciences includes expanding our offerings in the following key areas: 📜 Comprehensive IND submission support 🩺 Medical and regulatory strategy development 💡 Protocol design and clinical trial execution 💉Enhanced medical affairs, including Key Opinion Leaders (KOL) engagement, opening KOL labs, and advancing PDX models In addition to expanding SBH’s service offerings, Dr. Rashal will focus on supporting biotech startups, leading due diligence, and fostering opportunities for non-dilutive funding to ensure long-term success and sustainability. Her strategic insights and collaborative approach will play a key role in SBH Sciences’ continued growth and success. Welcome to the team, Dr. Rashal!